Clinical trials: Cutaneous T-cell Lymphoma
Mycosis Fungoides and Sézary Syndrome
Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.
- Trial name
- PROSPER (NCT05455931)
- Testing
- Poteligeo
- Where
- 19 sites in United States, Italy and 4 more
- Volunteers
- 73 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Lymphoma, T-Cell, Cutaneous
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma.
- Trial name
- NCT01433731
- Testing
- SHAPE (SHP-141) 0.1% BID, SHAPE (SHP-141) 0.5% BID, SHAPE (SHP-141) 1.0% BID
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- TetraLogic Pharmaceuticals
T Cell Lymphoma
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.
- Trial name
- NCT00877656
- Testing
- HuMax-CD4
- Volunteers
- 21 people
- Sponsor
- Emergent BioSolutions
Cutaneous T-cell Lymphoma
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
This study is being conducted to identify how much and how often pralatrexate, given with vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell lymphoma (CTCL) that has relapsed (returned after…
- Trial name
- NCT00554827
- Testing
- Vitamin B12, Folic Acid, Pralatrexate
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Acrotech Biopharma Inc.
Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00053105
- Testing
- cisplatin, cytarabine, methylprednisolone
- Where
- 7 sites in United States
- Sponsor
- Theradex
Lymphoma
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients…
- Trial name
- NCT00127101
- Testing
- vorinostat, Comparator: bexarotene
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
T-Cell Lymphoma
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in…
- Trial name
- NCT05442554
- Testing
- Brentuximab vedotin
- Where
- 4 sites in China
- Volunteers
- 10 people
- Sponsor
- Takeda
Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL.
- Trial name
- NCT04745234
- Testing
- Mogamulizumab
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 34 people
- Sponsor
- Kyowa Kirin, Inc.
Cutaneous T-cell Lymphoma (CTCL),
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia.
- Trial name
- NCT00501735
- Testing
- Forodesine 200 mg
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 144 people
- Sponsor
- BioCryst Pharmaceuticals
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
- Trial name
- NCT06149247
- Testing
- Hypericin, Mechlorethamine Topical Gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Soligenix
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL)
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies.
- Conditions
- Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04072458
- Testing
- L-Bcl-2 antisense oligonucleotide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bio-Path Holdings, Inc.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma
L19IL2/L19TNF in Skin Cancer Patients
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.
- Conditions
- BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin
- Trial name
- IntriNSiC (NCT05329792)
- Testing
- L19IL2/L19TNF
- Where
- 14 sites in France, Italy and 1 more
- Volunteers
- 70 people
- Sponsor
- Philogen S.p.A.
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Advanced Cancer
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics of escalating doses of the proteasome inhibitor NPI-0052 in patients with advanced malignancies including solid tumors, lymphomas…
- Trial name
- NCT00629473
- Testing
- NPI-0052 on Days 1, 8, 15 every 28 days, NPI-0052 on Days 1, 4, 8, 11 every 21 days, Dexamethasone
- Where
- 7 sites in Australia
- Volunteers
- 86 people
- Sponsor
- Celgene
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4 as a treatment for early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071071
- Testing
- HuMax-CD4
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genmab
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
- Trial name
- NCT00807495
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study
The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype in subjects who have…
- Trial name
- PRISM (NCT03837457)
- Testing
- Cobomarsen
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 8 people
- Sponsor
- miRagen Therapeutics, Inc.
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071084
- Testing
- HuMax-CD4
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 22 people
- Sponsor
- Genmab
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise…
- Conditions
- T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent
- Trial name
- NCT04712864
- Testing
- LB1901
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Legend Biotech USA Inc